Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02020941 · ClinicalTrials.gov registry record · Phase 2
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy
A Phase 2 study, sponsored by Attaya Suvannasankha.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02020941: Clinical Trial Phase 2 study, sponsored by Attaya Suvannasankha.
NCT02020941 is a Phase 2 study that was terminated before completion, run by Attaya Suvannasankha. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02020941, a Phase 2 study, was terminated before completion, sponsored by Attaya Suvannasankha.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase II trial studies how well carfilzomib works in treating patients with multiple myeloma in first relapse or refractory to first-line therapy. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
: Evaluate the overall response rate of patients receiving therapy. Patients are considered as having a response if their overall response is Partial Response or better. The percentage of patients achieving this and the exact 95% confidence interval will be calculated. Responses will be defined using the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC).
Interventions
- OTHER laboratory biomarker analysis
- DRUG dexamethasone
- DRUG carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Why NCT02020941 stopped before completion
NCT02020941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT02020941 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02020941 about?
NCT02020941 is a clinical study titled "Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy". This phase II trial studies how well carfilzomib works in treating patients with multiple myeloma in first relapse or refractory to first-line therapy. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02020941?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2013-09. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02020941?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dexamethasone (DRUG), carfilzomib (DRUG).
Who is sponsoring clinical trial NCT02020941?
This trial is sponsored by Attaya Suvannasankha, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02020941's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia